Peganum harmala (Syrian Rue)

Peganum harmala contains beta-carboline alkaloids including harmine and harmaline that inhibit monoamine oxidase enzymes. These compounds may influence neurotransmitter metabolism and glucose regulation through PPARγ pathway modulation.

Origin & History

Peganum harmala L. (Syrian rue) is a herbaceous perennial plant from the Zygophyllaceae family, native to Iran, North Africa, and other arid regions. The plant's seeds, bark, roots, and fruits contain beta-carboline alkaloids (2-7% total content), which are extracted using methods like reverse-phase high-performance liquid chromatography for therapeutic applications.

Historical & Cultural Context

In Iranian and North African folk medicine, Peganum harmala has been used for centuries, with seeds, bark, and roots employed for various therapeutic purposes. The plant's beta-carboline alkaloids have been linked to these traditional therapeutic applications, though specific historical uses and duration are not quantified in available literature.

Health Benefits

• May support blood sugar regulation through PPARγ pathway modulation (preliminary animal/in-vitro evidence only)
• Contains monoamine oxidase inhibiting compounds that could influence mood pathways (mechanistic studies, no human trials)
• Traditional use for various conditions in Iranian and North African medicine (historical use only, no clinical validation)
• Potential anti-inflammatory properties through Wnt signaling inhibition (in-vitro evidence only)
• May influence metabolic processes via cytochrome P450 enzyme modulation (pharmacological data only)

How It Works

The primary bioactive compounds harmine, harmaline, and harmalol reversibly inhibit monoamine oxidase A and B enzymes, potentially increasing serotonin, dopamine, and norepinephrine levels. These beta-carboline alkaloids also modulate PPARγ receptors, which regulate glucose metabolism and insulin sensitivity. Additional mechanisms include acetylcholinesterase inhibition and potential GABA receptor interactions.

Scientific Research

No human clinical trials, randomized controlled trials, or meta-analyses for Peganum harmala were identified in the available research. Current evidence is limited to pharmacological reviews of animal and in-vitro data, with researchers calling for clinical validation due to documented intoxication risks.

Clinical Summary

Human clinical evidence for Peganum harmala is extremely limited, with most research conducted in animal models and cell cultures. Animal studies suggest potential blood sugar lowering effects at doses of 200-400mg/kg, but these findings cannot be extrapolated to humans. In vitro studies demonstrate significant MAO inhibition with IC50 values around 10-50 μM for harmine. No randomized controlled trials have evaluated safety or efficacy in human subjects.

Nutritional Profile

Peganum harmala seeds contain approximately 3-6% total alkaloid content by dry weight, dominated by beta-carboline alkaloids: harmine (0.44-4.3% dry weight), harmaline (0.25-3.9% dry weight), and harmalol (0.1-0.4% dry weight), with tetrahydroharmine present in smaller trace amounts. Quinazoline alkaloids vasicine and vasicinone are present at approximately 0.1-0.3% combined. Crude protein content ranges from 18-25% dry weight, composed primarily of glutamic acid, aspartic acid, and arginine residue fractions. Crude fat content is approximately 8-15% dry weight, with linoleic acid (omega-6) and oleic acid comprising the majority of fatty acid fractions. Crude fiber is approximately 20-28% dry weight. Carbohydrate content is approximately 20-30% dry weight. Mineral content includes potassium (estimated 600-900 mg/100g dry weight), calcium (approximately 300-500 mg/100g), magnesium (approximately 150-250 mg/100g), iron (approximately 8-15 mg/100g), and zinc (approximately 3-6 mg/100g), though precise validated figures are limited in peer-reviewed literature. Flavonoids including rutin and isorhamnetin glycosides are present at low concentrations (estimated <0.5% dry weight). Bioavailability note: The beta-carboline alkaloids are rapidly absorbed orally but undergo significant first-pass hepatic metabolism; harmaline is more rapidly metabolized than harmine. The MAOI activity of these alkaloids substantially affects bioavailability of co-ingested tryptamine compounds. As a non-conventional food ingredient consumed primarily as a spice or medicinal preparation in very small quantities (typically 0.1-1g per use), macronutrient contributions to daily intake are negligible in typical culinary applications.

Preparation & Dosage

No clinically validated dosage ranges have been established for human use. Analytical studies report harmaline concentrations of 56.0 mg/g in seeds, 4.55 mg/g in fruits, and 0.54 mg/g in capsule walls, but safe human dosing remains unstudied. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Passionflower, St. John's Wort, Rhodiola, Ginkgo biloba, Ashwagandha

Safety & Interactions

Peganum harmala poses serious safety risks due to its MAO-inhibiting properties, potentially causing dangerous interactions with medications including SSRIs, SNRIs, and stimulants. Consumption may trigger hypertensive crisis when combined with tyramine-rich foods or certain drugs. The plant contains compounds that may cause nausea, vomiting, and hallucinations at higher doses. Pregnant and breastfeeding women should avoid use due to potential uterine stimulant effects and lack of safety data.